Search

Pulmatrix Inc

Slēgts

1.4 -0.71

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

1.38

Max

1.4

Galvenie mērījumi

By Trading Economics

Ienākumi

136K

-1M

EPS

-0.29

Darbinieki

2

EBITDA

126K

-1M

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-657K

5.1M

Iepriekšējā atvēršanas cena

2.11

Iepriekšējā slēgšanas cena

1.4

Pulmatrix Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 12. sept. 23:51 UTC

China's House Price Index YoY release on September 15 expected to show continued decline amid cautious market sentiment and rising global oil prices.

2026. g. 12. sept. 23:41 UTC

Philadelphia Fed Manufacturing Index Set for Release Amid Heightened Market Sensitivity to Inflation and Interest Rate Hike Expectations.

2026. g. 12. sept. 23:41 UTC

U.S. Building Permits Expected to Reach 1.41 Million for August Amid Mixed Housing Sentiment Ahead of September Release

2026. g. 12. sept. 23:41 UTC

Housing Starts Data Release on September 17, 2026, Expected to Show Continued Caution Amid High Mortgage Rates and Recent Declines.

2026. g. 12. sept. 23:41 UTC

Upcoming U.S. Building Permits Report on September 17, 2026, Expected to Reflect Economic Health Amid Stable Market Sentiment.

2026. g. 12. sept. 23:41 UTC

Upcoming Housing Starts Data Release Amid Rising Mortgage Rates Raises Concerns for U.S. Construction Market

2026. g. 12. sept. 23:21 UTC

U.S. Retail Sales Ex Autos Expected to Rise 0.5% in August Amid Mixed Economic Sentiment and Inflation Concerns

2026. g. 12. sept. 23:21 UTC

U.S. Import Prices Expected to Rise 0.2% Amid Inflation Concerns and Fed Rate Speculation Following Geopolitical Tensions

2026. g. 12. sept. 23:21 UTC

U.S. Export Prices Expected to Rise in August Amid Positive Economic Sentiment and Fed Rate Speculations

2026. g. 12. sept. 23:21 UTC

U.S. Retail Sales Expected to Rise 0.9% in August Amid Cautious Market Sentiment Following July's Decline

2026. g. 12. sept. 23:11 UTC

Canada's housing starts data release on September 16, 2026, expected at 235,000 units amid cautious market sentiment following July’s shortfall.

2026. g. 12. sept. 23:01 UTC

NY Empire State Manufacturing Index Set for Release Amid Mixed Economic Sentiment and Inflation Concerns on September 15, 2026.

2026. g. 12. sept. 23:01 UTC

Market Awaits ECB President Lagarde's Speech Amid Speculation of Future Rate Hikes and Leadership Changes Following Recent Interest Rate Increase.

2026. g. 12. sept. 22:51 UTC

Brazil's Central Bank Set to Announce SELIC Rate Decision Amid Global Monetary Tightening and Rising Inflation Concerns on September 14, 2026.

2026. g. 12. sept. 22:51 UTC

Japan's Core Inflation Rate Expected to Rise to 1.8% Amid Global Economic Pressures Ahead of Bank of Japan Meeting

2026. g. 12. sept. 22:51 UTC

Japan's Upcoming Inflation Rate Report Expected to Reflect Mixed Signals Amid Rising Energy Costs and Producer Price Fluctuations

2026. g. 12. sept. 22:41 UTC

Canada's August Inflation Rate Release on September 14 Expected to Show Continued Pressure Amid Geopolitical Tensions and Rising Oil Prices.

2026. g. 12. sept. 22:41 UTC

Canada's Core Inflation Rate Expected to Rise to 2.4% Amid U.S. Economic Indicators and Speculation of Fed Interest Rate Hikes

2026. g. 12. sept. 22:41 UTC

Rising U.S. 30-Year Mortgage Rates Exceed 7%, Threatening Housing Demand and Economic Growth Ahead of Key Central Bank Meetings

2026. g. 12. sept. 22:41 UTC

Canada's Inflation Rate Expected to Hold Steady at 0.0% Amid Global Economic Concerns Ahead of September Release

2026. g. 12. sept. 22:41 UTC

Macro News

The DAX 30 Index is lower in after-market trading, pressured by rising crude oil prices and concerns over Treasury yields and interest rate hikes.

2026. g. 12. sept. 22:31 UTC

Japan's trade deficit forecasted at -1052.6 billion yen for August 2026 amid rising import costs and negative market sentiment.

2026. g. 12. sept. 22:31 UTC

Japan's August Exports YoY Data Set for Release Amidst Cautious Market Sentiment and Economic Concerns

2026. g. 12. sept. 22:31 UTC

Japan's Machinery Orders Expected to Decline Amid Market Volatility and Inflation Concerns

2026. g. 12. sept. 22:31 UTC

Brazil's Retail Sales Report on September 15 Expected to Show Month-on-Month Growth Amid Inflationary Pressures

2026. g. 12. sept. 22:11 UTC

Bank of England Expected to Maintain Interest Rate at 0.667% Amid Global Economic Caution and Inflation Concerns

2026. g. 12. sept. 21:01 UTC

Oil (Brent) is trading lower during after-market hours, continuing a decline since Friday's close. The market shows weakness despite remaining above its 20-day moving average.

2026. g. 12. sept. 21:01 UTC

India's August Inflation Rate Release on September 14 Expected at 4.8%, Amid Rising Global Energy Costs and Geopolitical Tensions

2026. g. 12. sept. 21:01 UTC

EUR/PLN traded roughly flat during after-market hours, remaining around the middle of its one-month range with no specific news identified.

2026. g. 12. sept. 20:51 UTC

API Crude Oil Stock Change Data Release on September 15 Expected to Show Continued Inventory Decline Amid Easing Geopolitical Tensions and Inflation Concerns.

Salīdzinājums

Cenas izmaiņa

Pulmatrix Inc Prognoze

Vērtējuma vienprātība

By TipRanks

0 ratings

0

Pirkt

0

Turēt

0

Pārdot

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Pulmatrix Inc

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.
help-icon Live chat